315 related articles for article (PubMed ID: 33995372)
41. Onset of autoimmune lymphoproliferative syndrome (ALPS) in humans as a consequence of genetic defect accumulation.
Magerus-Chatinet A; Neven B; Stolzenberg MC; Daussy C; Arkwright PD; Lanzarotti N; Schaffner C; Cluet-Dennetiere S; Haerynck F; Michel G; Bole-Feysot C; Zarhrate M; Radford-Weiss I; Romana SP; Picard C; Fischer A; Rieux-Laucat F
J Clin Invest; 2011 Jan; 121(1):106-12. PubMed ID: 21183795
[TBL] [Abstract][Full Text] [Related]
42. The genetic landscape of the FAS pathway deficiencies.
Magerus A; Bercher-Brayer C; Rieux-Laucat F
Biomed J; 2021 Aug; 44(4):388-399. PubMed ID: 34171534
[TBL] [Abstract][Full Text] [Related]
43. A Spectrum of Clinical Findings from ALPS to CVID: Several Novel LRBA Defects.
Cagdas D; Halaçlı SO; Tan Ç; Lo B; Çetinkaya PG; Esenboğa S; Karaatmaca B; Matthews H; Balcı-Hayta B; Arıkoğlu T; Ezgü F; Aladağ E; Saltık-Temizel İN; Demir H; Kuşkonmaz B; Okur V; Gümrük F; Göker H; Çetinkaya D; Boztuğ K; Lenardo M; Sanal Ö; Tezcan İ
J Clin Immunol; 2019 Oct; 39(7):726-738. PubMed ID: 31432443
[TBL] [Abstract][Full Text] [Related]
44. Identification of new Fas mutations in a patient with autoimmune lymphoproliferative syndrome (ALPS) and eosinophilia.
Aspinall AI; Pinto A; Auer IA; Bridges P; Luider J; Dimnik L; Patel KD; Jorgenson K; Woodman RC
Blood Cells Mol Dis; 1999; 25(3-4):227-38. PubMed ID: 10575548
[TBL] [Abstract][Full Text] [Related]
45. Novel insights into FAS defects underlying autoimmune lymphoproliferative syndrome revealed by studies in consanguineous patients.
Ben-Mustapha I; Agrebi N; Barbouche MR
J Leukoc Biol; 2018 Mar; 103(3):501-508. PubMed ID: 29345341
[TBL] [Abstract][Full Text] [Related]
46. The contribution of rare copy number variants in FAS toward pathogenesis of autoimmune lymphoproliferative syndrome.
Jevtich K; Price S; Similuk M; Kulm E; Yan J; Setzer M; Jamal L; Franco LM; Ghosh R; Walkiewicz M; Rao VK
Blood Adv; 2022 Jul; 6(13):3974-3978. PubMed ID: 35476126
[TBL] [Abstract][Full Text] [Related]
47. Defective FAS-Mediated Apoptosis and Immune Dysregulation in Gaucher Disease.
Miano M; Madeo A; Cappelli E; Lanza F; Lanza T; Stroppiano M; Terranova P; Venè R; Bleesing JJH; Di Rocco M
J Allergy Clin Immunol Pract; 2020; 8(10):3535-3542. PubMed ID: 32702516
[TBL] [Abstract][Full Text] [Related]
48. Clincal, immunologic, and genetic features of an autoimmune lymphoproliferative syndrome associated with abnormal lymphocyte apoptosis.
Sneller MC; Wang J; Dale JK; Strober W; Middelton LA; Choi Y; Fleisher TA; Lim MS; Jaffe ES; Puck JM; Lenardo MJ; Straus SE
Blood; 1997 Feb; 89(4):1341-8. PubMed ID: 9028957
[TBL] [Abstract][Full Text] [Related]
49. The expanding spectrum of the autoimmune lymphoproliferative syndromes.
Oliveira JB
Curr Opin Pediatr; 2013 Dec; 25(6):722-9. PubMed ID: 24240292
[TBL] [Abstract][Full Text] [Related]
50. Scaling the tips of the ALPS.
Rieux-Laucat F; Kanellopoulos JM; Ojcius DM
Biomed J; 2021 Aug; 44(4):383-387. PubMed ID: 34438083
[TBL] [Abstract][Full Text] [Related]
51. Mutation of FAS, XIAP, and UNC13D genes in a patient with a complex lymphoproliferative phenotype.
Boggio E; Aricò M; Melensi M; Dianzani I; Ramenghi U; Dianzani U; Chiocchetti A
Pediatrics; 2013 Oct; 132(4):e1052-8. PubMed ID: 24043286
[TBL] [Abstract][Full Text] [Related]
52. Investigation of common variable immunodeficiency patients and healthy individuals using autoimmune lymphoproliferative syndrome biomarkers.
Roberts CA; Ayers L; Bateman EA; Sadler R; Magerus-Chatinet A; Rieux-Laucat F; Misbah SA; Ferry BL
Hum Immunol; 2013 Dec; 74(12):1531-5. PubMed ID: 23993982
[TBL] [Abstract][Full Text] [Related]
53. Somatic loss of heterozygosity, but not haploinsufficiency alone, leads to full-blown autoimmune lymphoproliferative syndrome in 1 of 12 family members with FAS start codon mutation.
Hauck F; Magerus-Chatinet A; Vicca S; Rensing-Ehl A; Roesen-Wolff A; Roesler J; Rieux-Laucat F
Clin Immunol; 2013 Apr; 147(1):61-68. PubMed ID: 23524443
[TBL] [Abstract][Full Text] [Related]
54. New advances in the diagnosis and treatment of autoimmune lymphoproliferative syndrome.
Teachey DT
Curr Opin Pediatr; 2012 Feb; 24(1):1-8. PubMed ID: 22157362
[TBL] [Abstract][Full Text] [Related]
55. A genetic disorder of lymphocyte apoptosis involving the fas pathway: the autoimmune lymphoproliferative syndrome.
Fleisher TA; Straus SE; Bleesing JJ
Curr Allergy Asthma Rep; 2001 Nov; 1(6):534-40. PubMed ID: 11895618
[TBL] [Abstract][Full Text] [Related]
56. Natural history of autoimmune lymphoproliferative syndrome associated with FAS gene mutations.
Price S; Shaw PA; Seitz A; Joshi G; Davis J; Niemela JE; Perkins K; Hornung RL; Folio L; Rosenberg PS; Puck JM; Hsu AP; Lo B; Pittaluga S; Jaffe ES; Fleisher TA; Rao VK; Lenardo MJ
Blood; 2014 Mar; 123(13):1989-99. PubMed ID: 24398331
[TBL] [Abstract][Full Text] [Related]
57. Deficiency of the Fas apoptosis pathway without Fas gene mutations is a familial trait predisposing to development of autoimmune diseases and cancer.
Ramenghi U; Bonissoni S; Migliaretti G; DeFranco S; Bottarel F; Gambaruto C; DiFranco D; Priori R; Conti F; Dianzani I; Valesini G; Merletti F; Dianzani U
Blood; 2000 May; 95(10):3176-82. PubMed ID: 10807785
[TBL] [Abstract][Full Text] [Related]
58. Case Report:
Rais A; Mekki N; Fedhila F; Alosaimi MF; Ben Khaled M; Zameli A; Agrebi N; Sellami MK; Geha R; Ben-Mustapha I; Barbouche MR
Front Immunol; 2021; 12():692107. PubMed ID: 34531853
[TBL] [Abstract][Full Text] [Related]
59. Stabilized
Xu X; Huang J; Zhao M; Chen H; Mo J; Zhou X; Su Q; Yu B; Huang Z
J Immunol Res; 2017; 2017():3469108. PubMed ID: 29250557
[TBL] [Abstract][Full Text] [Related]
60. Janus Kinase Inhibitor Tofacitinib Shows Potent Efficacy in a Mouse Model of Autoimmune Lymphoproliferative Syndrome (ALPS).
Yokoyama S; Perera PY; Terawaki S; Watanabe N; Kaminuma O; Waldmann TA; Hiroi T; Perera LP
J Clin Immunol; 2015 Oct; 35(7):661-7. PubMed ID: 26453583
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
